

# David R Nelson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11190879/publications.pdf>

Version: 2024-02-01

48  
papers

10,712  
citations

212478

28  
h-index

232693

48  
g-index

49  
all docs

49  
docs citations

49  
times ranked

8586  
citing authors

#	ARTICLE	IF	CITATIONS
1	Machine learning algorithms for predicting direct-acting antiviral treatment failure in chronic hepatitis C: An HCV-TARGET analysis. <i>Hepatology</i> , 2022, 76, 483-491.	3.6	16
2	Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial. <i>Journal of Viral Hepatitis</i> , 2022, 29, 795-806.	1.0	1
3	Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C. <i>Hepatology Communications</i> , 2021, 5, 203-216.	2.0	14
4	Willingness to participate in research among black patients with liver disease: A national cross-sectional study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 982-993.	1.0	2
5	High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. <i>American Journal of Gastroenterology</i> , 2021, 116, 1896-1904.	0.2	8
6	The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders. <i>Hepatology</i> , 2021, 74, 566-581.	3.6	9
7	Linkage of resistance-associated substitutions in GT1 sofosbuvir+ NS5A inhibitor failures treated with glecaprevir/pibrentasvir. <i>Journal of Hepatology</i> , 2021, 75, 820-828.	1.8	1
8	Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. <i>Gastroenterology</i> , 2019, 157, 1506-1517.e1.	0.6	32
9	Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic. <i>Annals of Hepatology</i> , 2019, 18, 304-309.	0.6	28
10	Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1027-1030.	1.0	2
11	Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. <i>Contemporary Clinical Trials</i> , 2017, 57, 58-68.	0.8	13
12	Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. <i>Gut</i> , 2017, 66, 1844-1852.	6.1	69
13	Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis. <i>Journal of Hepatology</i> , 2017, 67, 700-707.	1.8	11
14	Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2017, 166, 637.	2.0	540
15	Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. <i>New England Journal of Medicine</i> , 2017, 377, 1448-1455.	13.9	348
16	HCVso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection. <i>Clinical and Experimental Gastroenterology</i> , 2016, Volume 9, 351-363.	1.0	3
17	On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir. <i>Liver International</i> , 2016, 36, 1611-1618.	1.9	20
18	HCV Council – critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. <i>Liver International</i> , 2016, 36, 488-502.	1.9	4

#	ARTICLE	IF	CITATIONS
19	Hepatitis C virus: how to provide the best treatment with what I have. <i>Liver International</i> , 2016, 36, 58-61.	1.9	4
20	Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 776-783.	2.9	45
21	Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. <i>Liver International</i> , 2016, 36, 807-816.	1.9	270
22	L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. <i>Journal of Infectious Diseases</i> , 2016, 213, 1240-1247.	1.9	86
23	Development of sofosbuvir for the treatment of hepatitis C virus infection. <i>Annals of the New York Academy of Sciences</i> , 2015, 1358, 56-67.	1.8	31
24	Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients. <i>Liver International</i> , 2015, 35, 65-70.	1.9	16
25	All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY phase III study. <i>Hepatology</i> , 2015, 61, 1127-1135.	3.6	598
26	Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 336-344.	1.1	7
27	Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. <i>Lancet, The</i> , 2015, 386, 1537-1545.	6.3	625
28	Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET. <i>Journal of Hepatology</i> , 2015, 62, 286-293.	1.8	86
29	Infrequent Development of Resistance in Genotype 1 Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials. <i>Clinical Infectious Diseases</i> , 2014, 59, 1666-1674.	2.9	199
30	Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2014, 370, 1483-1493.	13.9	1,241
31	Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. <i>New England Journal of Medicine</i> , 2014, 370, 222-232.	13.9	262
32	Direct-Acting Antiviral Agents and the Path to Interferon Independence. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 728-737.	2.4	34
33	Treatment of HCV with ABT-450/Ombitasvir and Dasabuvir with Ribavirin. <i>New England Journal of Medicine</i> , 2014, 370, 1594-1603.	13.9	816
34	Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2014, 370, 211-221.	13.9	1,065
35	Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. <i>Lancet, The</i> , 2013, 381, 2100-2107.	6.3	265
36	Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. <i>Lancet Infectious Diseases, The</i> , 2013, 13, 401-408.	4.6	313

#	ARTICLE	IF	CITATIONS
37	Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options. <i>New England Journal of Medicine</i> , 2013, 368, 1867-1877.	13.9	992
38	Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy. <i>Hepatitis Research and Treatment</i> , 2012, 2012, 1-21.	2.0	4
39	Steatosis Is an Independent Predictor of Relapse Following Rapid Virologic Response in Patients With HCV Genotype 3. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 688-693.	2.4	47
40	Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2011, 365, 1014-1024.	13.9	716
41	Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. <i>Laboratory Investigation</i> , 2011, 91, 598-608.	1.7	111
42	An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2011, 54, 1433-1444.	3.6	961
43	Characterization of Anti-HCV Antibodies in IL-10-Treated Patients. <i>Viral Immunology</i> , 2010, 23, 359-368.	0.6	4
44	Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells. <i>Laboratory Investigation</i> , 2007, 87, 582-590.	1.7	63
45	Pathogenesis of recurrent hepatitis C after liver transplantation. <i>Current Hepatitis Reports</i> , 2005, 4, 138-144.	0.3	1
46	An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection. <i>Hepatology</i> , 2004, 40, 1062-1071.	3.6	517
47	Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. <i>Hepatology</i> , 2003, 38, 859-868.	3.6	162
48	THE IMMUNOPATHOGENESIS OF HEPATITIS C VIRUS INFECTION. <i>Clinics in Liver Disease</i> , 2001, 5, 931-953.	1.0	50